A randomized, double‐blind, placebo‐controlled, parallel‐group, enriched‐design study of nabiximols* (Sativex®), as add‐on therapy, in subjects with refractory spasticity caused by multiple sclerosis
Background: Spasticity is a disabling complication of multiple sclerosis, affecting many patients with the condition. We report the first Phase 3 placebo‐controlled study of an oral antispasticity agent to use an enriched study design.
